PSMD6

Across TCGA pan-cancer cohorts, PSMD6 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PSMD6’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PSMD6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PSMD6 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

LIHC, KIRC, and COAD are the cancer types where PSMD6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PSMD6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	III,IV	+0.706	<.001	9	view →
KIRC	Male	II,III,IV	−0.596	<.001	9	view →
COAD	Female	II,III,IV	+0.562	<.001	9	view →
BRCA	All	All	+0.174	<.001	6	view →
KICH	All	All	−0.669	<.001	5	view →
STAD	All	II,III,IV	+0.392	.010	3	view →
CHOL	All	All	+0.692	.007	2	view →
READ	All	III,IV	+0.575	.044	2	view →
KIRP	Male	All	−0.351	.002	2	view →
BLCA	Male	All	+0.256	.033	2	view →
THCA	All	All	−0.133	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PSMD6–LIHC

Open the LIHC breakdown →